Boric Acid Osteoblast Model for Brittle Bone Disease Research
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for brittle bone disease, such as osteogenesis imperfecta, are limited by insufficient model development and ethical challenges in human studies, necessitating the need for new compounds and experimental models to effectively address the disease's structural disorder of type 1 collagen.
Innovation Solution
Development of an in-vitro model using differentiated osteoblast cells treated with hydroxy-urea and boric acid to simulate the effects of boric acid on brittle bone disease, providing a low-cost alternative for studying cellular responses before transitioning to in-vivo models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human studies are conducted for brittle bone disease treatment, then therapeutic effectiveness can be directly evaluated, but ethical problems and patient inclusion difficulties arise
Solution Approach 1:
The patent creates an in-vitro model using osteoblast cells that replicates the brittle bone disease condition through hydroxyurea treatment, allowing therapeutic effects to be studied in a controlled cellular environment without involving human patients, thus avoiding ethical problems while maintaining research validity
2Reliability
If in-vivo models are used for brittle bone disease research, then disease progression can be observed, but model development is insufficient and costly
Solution Approach 1:
The patent develops an in-vitro cellular model using osteoblast cells treated with hydroxyurea to simulate brittle bone disease, providing a simpler, more cost-effective, and ethically sound alternative to complex in-vivo animal models while maintaining the ability to observe disease-relevant cellular processes
Solution Approach 2:
The patent employs a simplified cellular model system that is easier and cheaper to establish than in-vivo models, allowing rapid experimentation and iteration without the long-term commitments and high costs associated with animal research
3Strength
If biphosphonates are used to treat brittle bone disease, then bone breaking frequency decreases, but treatment limitations and side effects occur
Solution Approach 1:
The patent investigates boric acid as a potential therapeutic agent, examining its effects on osteoblast cell proliferation, differentiation, and matrix production at controlled concentrations, which may provide alternative mechanisms for improving bone strength without the limitations of existing biphosphonate treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The in-vitro model effectively enhances osteoblast function and protection against cellular aging, demonstrating improved cellular morphology and increased production of osteonectin and osteocalcin, indicating potential therapeutic benefits of boric acid for treating brittle bone disease.
Implementation Method 1
Boron stabilizes cell membrane and regulates carrier mechanisms in the membrane
Implementation Method 2
Boron activates 1,25(OH)D3 production and thus, it increases bone mineralization
Implementation Method 3
Differentiated osteoblast cells were used in the in-vitro model
Data Source
AI summary
The present invention provides usage of boric acid in a method of brittle bone disease treatment. In the present invention, moreover, there is a new brittle bone disease (osteogenesis imperfecta) in-vitro model for observing the effect of boric acid on brittle bone disease.